October 3, 2022

COSM PROFILE

OUR NEW PROFILE IS:   (NASDAQ: COSM)

COSM just posted $3.7 million in profits for the first six months of 2022

MASSIVE SHIFT TO PREVENTIVE HEALTHCARE COULD PROPEL THE GLOBAL NUTRACEUTICALS MARKET TO $1 TRILLION BY 2030

Yahoo has the Market cap on COSM at just 9.6M 

The Company Just Achieved Annual Revenues of $56 Million and Reported a 202.42 % Increase in Adjusted EBITDA and Positive Operating Income for the First Half of 2022

___________________

Hello Everyone,

We have another profile for today’s session that we want you to take a look at.

This one has a number of catalysts worth looking at for today.

It trades on a major exchange and is sitting under .50 and in a profitable financial situation.

I want you to pull up COSM immediately.  

Take a look at some of the catalysts in play:

Amazon: Cosmos Health Inc. (COSM) just launched its “Sky Premium Life” nutritional supplement products on Amazon in the United States (25), tapping into the 90 million Amazon Prime subscribers in the US, and more than 300 million active customers worldwide. (24)

Booming Market: It is estimated that 77% of Americans use dietary supplements (27)while the U.S. nutraceutical market is expected to hit $138.0 billion by 2027(25) and the global nutraceuticals market is expected to reach $1 trillion by 2030. (23)

Gross Profits: Cosmos Health Inc. (COSM) just reported a 202.42% increase in adjusted EBITDA with gross profits increasing by 23.0% to $3.7 million for the six months ended June 30, 2022.(26)

Value: Cosmos Health Inc. (COSM) is a very small company with a market cap just under $9.3 million according to Yahoo finance. (31) Not bad for a company that just posted $3.7 million in profits for the first six months of 2022. (26)

Upside Potential: The company was listed on the NASDAQ on February 28th, 2022 when it reached an intraday high of $3.92 and closed around $.36 on September 2nd, 2022 according to Barchart.com. That means Cosmos Health Inc. (COSM) is approximately 988% off its 52-week high. Can you say potential upside?.

Couple all of this with a tiny market cap and strong financial news, this one has potential moving forward.

The rising demand for dietary supplements and functional foods is expected to be a major driving force in the preventive healthcare market. (19)

In addition, a positive outlook toward medical nutrition, given its growing use in the treatment of cardiovascular disorders and malnutrition, is likely to boost the growth of the nutraceuticals market in the coming years. (19)

The rising geriatric population, rising healthcare costs, changing lifestyles, food innovation, and expectations regarding higher prices will propel the growth of the nutraceuticals market in the upcoming years. (19)

Consumers have a very positive attitude toward nutraceuticals, nutritional supplements, and functional foods – owing to the additional health and wellness benefits that these products provide, driving the market’s growth. (19)

During the pandemic period, demand for nutraceuticals expanded globally due to the flexibility of storage choices, the need for combination formulations with various benefits, increasing consumer education levels, educated consumers, and the growth in health concerns among informed consumers.(19)

Moreover, rising healthcare costs, combined with an aging global population, are expected to drive the global nutraceuticals industry’s growth over the next decade. (19)

Source 20

One company that could benefit from the massive shift to Nutraceuticals is Cosmos Health Inc. (NASDAQ: COSM). (18)

Cosmos Health Inc. is an international healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. The company is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” (21)

Cosmos Health Inc. (NASDAQ: COSM) offers broad exposure to the pharmaceutical sector as well, through a broad line of branded generics and over-the-counter (OTC) medications. (21)

In addition, Cosmos Health Inc. is involved in the healthcare distribution sector through its subsidiaries in Greece and the UK serving retail pharmacies and wholesale distributors.

The company is strategically focusing on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. (21)

Cosmos Health Inc. (NASDAQ: COSM) specifically focuses on the following business segments:

The Global Nutraceuticals Market Expected To Reach $1 Trillion by 2030 (23)

Source 22
The global nutraceuticals market was estimated to be $498.86 billion (US) in 2021 and is expected to reach $1 trillion by 2030, at a compounded annual growth rate of 8.33% from 2022 to 2030. (23)

Cosmos Health Inc. (NASDAQ: COSM) could potentially be well positioned for this unprecedented opportunity in the nutraceuticals market.

Market Overview: Nutraceuticals is a comprehensive umbrella term which is used to label any product acquired from food origin with additional health advantages over and above the basic nutritious value available in foods. (23)

Nutraceuticals can be regarded as non-precise biological remedies used to boost general health, regulate indications and avert malignant developments. (23)

Nutraceuticals can be segmented on the foundation of their natural basis, pharmacological circumstances, as well as chemical structure of the products. Most often nutraceuticals are organized in the following classes: functional food, dietary supplements, pharmaceuticals, and medicinal food. (23)

According to a report from Precedence Research, crucial factors accountable for nutraceutical market growth are: (23)

Cosmos Health Inc. (COSM) Launches First Sky Premium Life Nutritional Supplement Products on Amazon in the United States (25)

Source 24

In August 2022, Cosmos Health Inc. launched the first of its “Sky Premium Life” products on Amazon in the United States. The company targets having all 85 product SKUs listed on Amazon by year end. (25)

“We are excited to officially launch our Sky Premium Life products on Amazon in the United States,” stated Greg Siokas, Chief Executive Officer of Cosmos Health. (25)

“Sky Premium Life products are currently being shipped and will arrive in the U.S. in early September. Importantly, we have executed on our strategy in the U.S. by launching our products on Amazon in the third quarter of 2022 as stated previously. We expect to have all 85 SKUs listed on Amazon by the end of this year. We are accelerating our global roll-out strategy as we launch our products worldwide. Earlier this year, we successfully introduced our products on Amazon in the U.K. and Singapore. Our key objective is to grow internationally, as we continue to leverage our robust global logistics and distribution capabilities, while expanding our customer base worldwide.” (25)

To view the full Sky Premium Life product line click here.

Amazon News: This could prove to be a complete game changer for Cosmos Health Inc.(COSM) as the platform has 90 million Amazon Prime subscribers in the US, and more than 300 million active customers worldwide. (24)

Cosmos Health Inc. (COSM) Reports 202.42 % Increase in Adjusted EBITDA and Positive Operating Income for the First Half of 2022 (26)

Cosmos Holdings Inc is engaged in the research, development, and commercialization of nutraceutical and pharmaceutical products and medicines world-wide. It offers a proprietary, internally developed, nutraceutical line and over-the-counter drugs and branded and generic medicines. The company’s focus will be on continued research & development of its nutraceutical brand (Premium Sky Life), geographic expansion, sales channel diversification, and year-over-year growth of its branded pharmaceuticals, Over-the-Counter medicines, and generic pharmaceuticals. Its products are sold directly to the consumer via ecommerce and are sold through wholesale drug distributors, and wholesalers and retail healthcare providers.
Greg Siokas, Chief Executive Officer of Cosmos Health, stated,

“We increased our profitability for the first half of 2022 due to the increase of gross profit margin to 14.2% from 11.5% for the respective period of 2021. This increase is attributed mainly to the organic growth of our proprietary nutraceutical brand, Sky Premium Life® (“SPL”). We achieved positive income from operations of $0.2 million for the first half of 2022 compared to a loss of $3.1 million in the same period last year and positive EBITDA of $0.8 million for the first half of 2022 compared to a loss of $2.8 million for the same period last year. Gross profit increased by 23.0% to $3.7 million for the six months ended June 30, 2022. We continue to carefully manage expenses and reduced operating expenses by nearly 43.7% and 41.9% for the three and six months ended June 30, 2022, respectively.”

“During the quarter, we launched a new premium line of nutritional supplements, Mediterranation. The Mediterranation line uses organic herbs and plant extracts such as crataegus, hibiscus, dittany of Crete, oregano, mastic and kritamos, found in specific regions in Greece and the Mediterranean. These unique formulations contain a proprietary blend of vitamins and minerals and are made with the highest quality raw materials. There is high demand among consumers for supplements that utilize high quality Mediterranean ingredients, such as polyphenols, which possess antioxidant and anti-inflammatory properties. We expect the launch of the Mediterranation line will further enhance our growth strategy and we look forward to expanding the product line into new global markets through our growing distribution channels. We also launched our SPL products on Amazon Singapore and are in the process of launching on Amazon United States and Amazon Canada in the third quarter of 2022. These new markets provide an untapped growth opportunities and new audiences for our proprietary SPL brand. Our goal is to grow our portfolio of branded nutraceuticals and reach up to 150 SKUs by the end of 2022. We look forward to launching our high-quality nutraceutical products into other new international markets this year, by leveraging our robust global logistics and distribution capabilities.”

“Most recently we announced that we have rebranded and changed our name to Cosmos Health to better reflect the Company’s evolution into an innovative global healthcare group with a focus on improving people’s lives. Through our vertically integrated ecosystem, the enhancements we made with cutting edge technologies for the development of our pharmaceutical and nutraceutical products enable the Company to implement our goal of becoming a global healthcare group, committed to human health needs.”

“The Cosmos Health brand marks a new chapter in the Company’s evolution and better reflects our commitment towards a leading, highly scalable and innovative global healthcare group based on our R&D partnerships, fully licensed production facilities and fast deployment to distribution channels. This is in alignment with the Company’s recent announcements about our R&D partnership with CloudPharm and proposed acquisition of Cana Laboratories, a fully licensed Good Manufacturing Practices (GMP) medical manufacturing facility with outstanding scientific personnel, as we execute on our goal of becoming a leading global healthcare group,” concluded Greg Siokas, Chief Executive Officer of Cosmos Health.

Cosmo introduces new line of premium supplements that leverage the passion for everything Mediterranean

For the fifth year in a row, US News & World Report in January of 2022 ranked the Mediterranean diet No. 1 in multiple categories, including best for heart health, best for diabetes and best overall diet for weight loss. (12)

Even the prestigious Mayo clinic has declared the diet heart healthy (14) and for good reason…
The Mediterranean Basin has a very unique climate found in only a few places in the world. It is sunny, hot, and dry in the summer, with cold and wet winters.(15) That’s what makes the herbs, plants and pretty much everything from the region so in-demand.

On April 12, 2022, Sky Premium Life, Cosmos’ proprietary luxury nutritional supplement product line, launched Mediterranation, a new premium line of nutritional supplements. That can leverage the awareness of the extremely popular Mediterranean diet with a full line of supplements. (13)
High demand. High quality. Excellent revenue potential.

“There is high demand among consumers for supplements that utilize high quality Mediterranean ingredients, such as polyphenols, which possess antioxidant and anti-inflammatory properties. We carefully selected ingredients that have demonstrated positive effects, ranging from gut health, to aging, diabetes and cardiovascular disease,”

stated Greg Siokas, Chief Executive Officer of Cosmos Holdings.

“We created Mediterranation with good health in mind, utilizing unique formulations, and a specialized extraction process following strict pharmaceutical standards. We expect the launch of the Mediterranation line will further enhance our growth strategy and we look forward to expanding the product line into new global markets through our growing distribution channels.” (13)

Cosmos Health Inc. (COSM) Invests in Advanced Technologies to Expand Productivity(11)

A few months back, Cosmos made a HUGE announcement in regards to installing a “State-of-the-Art” automated fulfillment system at their logistics center in Greece.

The fully automated fulfillment system is designed to process complex orders with precision and speed, leading to increased performance while drastically lowering error rates.

The system can process up to 40,000 products per hour and can accommodate a variety of packaging shapes and sizes.

Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated,

“With a fully robotic system in place, CosmoFarm’s logistic center can now process orders at higher speeds and higher quality, even at peak times. This is critical to maintain the quality of our service while scaling our product offerings and client base. This installation reflects our commitment to invest in advanced technologies that substantially expand our current productivity and throughput, supporting our growth and improving the overall efficacy of our deliverables.” (11)

CosmoFarm, headquartered in Athens, Greece is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. CosmoFarm’s core activity is sourcing, procuring, and distributing branded and generic medicines, over-the-counter (OTC) pharmaceuticals, food supplements, and medical devices to its growing network of more than 1,130 pharmacies.

Now, to the Bread and Butter: Cosmos Health Inc. (COSM) Has a Comprehensive Strategy

foundation of Cosmos’ operating strategy is the optimization and growth of its pharmaceutical sourcing and distribution businesses. As Cosmos continues devoting significant resources to improve its operating and capital efficiencies, it believes it’s well-positioned in size and breadth to continue growing its trading businesses.

Sourcing and distribution, including specialty pharmaceuticals, is what Cosmos sees as the anchor of its growth and position in the pharmaceutical supply channel. Cosmos provides superior services and delivers value-added products, which improve the efficiency and competitiveness of healthcare providers. In turn, this aids the pharmaceutical supply channel to better provide healthcare to patients.

Cosmos Health Inc. (COSM) is Also Very Well Known for the Following 3 Subsidiaries Under its Belt: (8)

Sky Pharm SA:

Sky Pharm SA is a Thessaloniki, Greece-based pharmaceutical trading firm. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. Cosmos buys from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers and then exports them to European markets where demand and prices are substantially higher.

DHNDecahedron Ltd.:

Decahedron Ltd. is a UK-incorporated pharmaceutical wholesaler. It is audited by the MHRA under European GDP (Good Distribution Practices). It is also a full member of the EAEPC and has been audited by TÜV on its behalf. Decahedron imports and exports branded, generic and unlicensed POM, OTCs, and medical devices worldwide. It also participates in governmental tenders and registers dossiers in new territories. This subsidiary’s network consists of roughly 25 clients and vendors expanding to 9 countries, including Germany, UK, Denmark, The United Arab Emirates, Germany, Italy, France, Singapore, and Ireland.

Cosmofarm:

Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area.

Could Cosmos Health Inc. (COSM) Climb 988% Back To $3.92?

Taking a look at the chart above (from StockCharts.com) and observing the technical analysis you can clearly see the following moving averages:

– 50 day moving average at $.38
– 120 day moving average at $.94
– 20 day exponential moving average $.36 (key line of potential resistance)

But what you don’t see – is what this actually means in dollars and cents.

Meaning, that if Cosmos Health Inc. (COSM) trends above its first line of resistance at the $.36 range… then the next line of potential resistance may be all the way at $.94, which, if reached, would represent an approximate 161% potential move.

Furthermore, if Cosmos Health Inc. (COSM) were to climb back to $3.92 from $.36 (closing price as of 9/2/22), it would represent an approximate 988% move.
Now, I’m not saying that Cosmos Health Inc. (COSM) is going to reach those levels today, tomorrow, or next week, but you need to be aware of its potential upside from current trading levels.

You see, from a technical analysis perspective, Cosmos Health Inc. (COSM) could be at the beginning of what’s called a “Descending Triangle Breakout Strategy.”

…And by definition, the “Descending Triangle Breakout Strategy,” as the name suggests, involves the anticipation of a breakout from the descending triangle pattern. (31)

This strategy uses a very simple combination of trading volumes and asserting the trend, which can be used to capture short term vertical moves.(31)

The basic premise of using this strategy is to look at volume once you’ve identified the pattern. You can typically observe that volume begins to diminish toward the end of the descending triangle pattern formation. (31)

Massive Shift To Preventive Healthcare Could Propel The Global Nutraceuticals Market To $1 Trillion By 2030. (17)

One company that could be extremely well positioned for this unprecedented opportunity is Cosmos Health Inc. (NASDAQ: COSM)…(18)

RECENT NEWS

MANAGMENT

Mr. Grigorios Siokas has over 15 years’ experience in the pharmaceutical industry. Since 2014, he has served as the CEO and Operations Manager of SkyPharm SA a wholly-owned subsidiary of the Company. SkyPharm SA is a pharmaceutical company located in Greece that mainly exports medicines from Greece to other European countries, such as Germany, England and Denmark.

Prior to 2014, Mr. Siokas worked in a variety of sectors of the pharmaceutical industry mostly in the trading of medicines in Greece and other European countries. Additionally, since 2000 he has been a major shareholder in various pharmaceutical companies such as: Ippokratis Pharmaceuticals, (annual sales of over € 78 million); Thrakis Pharmaceuticals, (annual sales of over € 20 million); Thessalias Pharmaceuticals, (annual sales of over € 18 million); and ZED Pharma SA, (annual sales of over € 35 million).

During the 1990s, Mr. Siokas founded and operated a marble wholesale import – export company in Germany. Within a period of two years he became the 4th biggest Greek marble importer in Germany. He also ran a Tour Operation with many different airlines, serving millions of customers.

Mr. Grigorios Siokas has Bachelor’s Degree in Geology from the Aristotle University of Thessaloniki, Greece. He received a Master’s in management and finance from the University of Stuttgart and the University of Tuebigen, Germany and has served in the Greek Army.

Dimitrios Goulielmos joined us as CEO and Director on September 27, 2013. Since January 1991, he has been the principal attorney at the law firm of Goulielmos D. & Partners. He contributes to the Board the benefits of his legal, academic, and business background.

Mr. Goulielmos is a fourth generation attorney. He received his law degree with Excellency from the Aristotle University of Thessaloniki in 1988. He did post graduate studies for International transactions and Company law at Paris, France and at the LSE of London, England.

In 2004 he was elected Vice-president of EUROPECHE, the organization that was established by the European Committee for the consultation and proposal of solutions in the sector of Community Fishery.

The same year he was also elected as National representative of Hellas in the MEDISAMAK, the organization responsible for all Mediterranean countries, in the sector of Fishery.

In year 2007 he was re-elected as Vice-president of EUROPECHE. He is a member of the social dialogue group of ACFA, of EU on labor affairs.

He is an honorary lifetime member of International Who’s Who Historical Society.

Mr. Goulielmos has extensive experience in law, international deals, mergers, acquisitions, negotiations, international application of licenses, and real estate management which he will contribute to the Board.

Mr. Demetrios G. Demetriades was elected as Secretary and Director of the Company.

Since January 2003, Mr. Demetriades, age 48, has been Director of Highlander Spring Trading Ltd, a trading company.

From November 2000 to December 2002 he was Marketing Director of Eurolink Securities Ltd which was involved in trading in the Cyprus Stock Exchange.

From January 1995 to November 2000 he was Supervising Officer of Laiki Factors Ltd, a financing company.

As a member of the board, Mr. Demetriades contributes the benefits of his trading, executive leadership and management experience.

On November 18, 2016, John J. Hoidas was appointed as a member of the Board of Directors of Cosmos Holdings. Mr. Hoidas is a registered broker dealer. John J. Hoidas began working on the floor of the CME in 1989 as a runner and by 1995 started trading the S&P 500 and GSCI Index Futures for 9 years. In 2004, he transitioned to wealth management at American Express Financial Advisors which spun off to Ameriprise. In 2010, he joined Kingsbury Capital & began raising money for late-stage pre-IPO companies such as Organovo (ONVO), Invivo Therapeutics (NVIV) and Matinas BioPharma (MTNB) to name a few. John previously served as a Senior Vice President at Uhlmann Price. At Uhlmann Price Securities, he has raised capital for startups such as Video Gaming Co; Gazillion, Inc., Liquidspace, and Revel Systems.
Dr. Aslidis was appointed as a member of the Board of Directors of Cosmos Holdings on April 28, 2022.  Dr. Anastasios Aslidis currently serves as the Chief Financial Officer and Treasurer, as well as a member of the Board of Directors of EuroDry (EDRY) since 2018. He is Chief Financial Officer, Treasurer and a member of the Board of Directors of Euroseas (Nasdaq: ESEA) since September 2005. Furthermore, Dr. Aslidis has been a director of Vianair Inc., a private company active in airspace design and airport operations analysis since 2017. Prior to joining Euroseas, Dr. Aslidis was a partner at Marsoft Inc., an international consulting firm focusing on investment and risk management in the maritime industry. Dr. Aslidis has more than 30 years of experience in the maritime industry. He also served as consultant to the Boards of Directors of public and private companies advising on strategy development, asset selection and investment timing. Dr. Aslidis holds a Ph.D. in Ocean Systems Management (1989) from the Massachusetts Institute of Technology, M.S. in Operations Research (1987) and M.S. in Ocean Systems Management (1984), also from the Massachusetts Institute of Technology, and a Diploma in Naval Architecture and Marine Engineering from the National Technical University of Athens (1983).

Sincerely,

The Viral Stocks Team

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS A WHOLLY OWNED SUBSIDIARY OF GLOBAL COIN MEDIA, LLC.  HEREIN REFERRED TO AS GCM, LLC.  WE ARE A NEVADA COMPANY. 
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.  WE HAVE BEEN COMPENSATED A FEE OF TWENTY SEVEN THOUSAND FIVE HUNDRED USD FOR A ONE DAY COSM AWARENESS CAMPAIGN BY A THIRD PARTY, TD MEDIA, LLC.   NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: GCMLLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD GCM, LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. GCMLLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND GCM, LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD GCM, LLC.  STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.GCM, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. GCM, LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND GCM, LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.IN PREPARING THIS PUBLICATION, GCM, LLCHAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, GCM, LLCAND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. GCM, LLCIS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS GCM, LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. GCM, LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Source List